#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Short-bowel syndrome Graft versus host disease KBG syndrome Desmoplastic small round cell tumour Prophylaxis against transplant rejection Optic glioma Juvenile chronic myelomonocytic leukaemia Kearns-Sayre syndrome Cutaneous lupus erythematosus Hepatoblastoma Haemophilia A without inhibitors Anaplastic thyroid cancer Obesity Canavan disease Ventricular tachycardia More trials…

    Learn about Rare Diseases

    Glomerulonephritis rapidly progressive – Diagnostics Marginal zone lymphoma – Treatment Bronchopulmonary dysplasia Fabry’s disease – Trials in Disease Mucopolysaccharidosis – Life with Disease Leiomyosarcoma recurrent – Basic Information Nephrotic syndrome – Treatment Usher’s syndrome – Treatment Bronchiolitis obliterans syndrome – Basic Information Angiosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxazepam Zibotentan L-Histidine Adrc001 Irinotecan Ergocalciferol Clascoterone Carcik-Cd19 Cells Dabrafenib Mesylate ARFOLITIXORIN Ale.c04 Taletrectinib Tapderimotide Ly3484356 Vincristine Sulfate Propafenone Hydrochloride ADS-019 Zamtocabtagene Autoleucel Blood And Related Products Almagate More therapies…

    Learn about Your Condition

    Actinic keratosis Metastases to liver Autoimmune haemolytic anaemia Anxiety disorder Acute leukaemia Substance use disorder Bipolar disorder Systemic scleroderma Lupus nephritis Adenocarcinoma Coeliac disease Tuberous sclerosis complex Glycogen storage disorder Eosinophilic gastritis Mumps More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    Belgium Czechia Denmark Estonia Finland France +12

  • Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Autologous Tumour-Infiltrating Lymphocytes
    • Aldesleukin
    • Fludarabine
    Belgium France Germany Italy The Netherlands Spain

  • Study on Tislelizumab for Cancer Patients with Molecular Residual Disease After Standard Treatment

    Recruiting

    3 1 1
    Investigated Drugs:
    • Sodium Chloride
    • Tislelizumab
    France

  • Study of EXL-01 and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immunotherapy

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Exl01
    • Nivolumab
    France

  • Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Lazertinib
    • Pemetrexed Disodium
    • Amivantamab
    France Germany Italy Spain

  • Study of NVL-520 for Patients with Advanced ROS1-Positive Lung Cancer and Other Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Zidesamtinib
    Belgium France Germany Italy The Netherlands Spain
Previous Page
1 … 12 13 14 15 16 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!